Drugs / Simmitinib
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04058587 | Jun 2020 → Jan 2023 | neoplasm | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06577376 | Aug 2024 → Aug 2026 overdue | gastroesophageal adenocarcinoma | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06132217 | Jan 2024 → Jan 2027 expected | neoplasm | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06512428 | Mar 2024 → Jan 2026 overdue | esophageal squamous cell carcinoma | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06656091 | Oct 2024 → Jan 2027 expected | esophageal squamous cell carcinoma | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Simmitinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06577376 ↗ |
| Action | Inhibit | “the FGFR/KDR/CSF1R multi-target inhibitor Simmitinib” NCT04058587 ↗ |
| Modality | Small molecule | “A novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR2, KDR), and colony-stimulating factor 1...” NCT06577376 ↗ |
| Route | Oral | “oral Simmitinib” NCT04058587 ↗ |
| Target | CSF1R | “the FGFR/KDR/CSF1R multi-target inhibitor Simmitinib” NCT04058587 ↗ |
| Target | KDR | “the FGFR/KDR/CSF1R multi-target inhibitor Simmitinib” NCT04058587 ↗ |